Literature DB >> 15247469

Cancer immunotherapy: a treatment for the masses.

Joseph N Blattman1, Philip D Greenberg.   

Abstract

Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247469     DOI: 10.1126/science.1100369

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  170 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming.

Authors:  Jacques Banchereau; LuAnn Thompson-Snipes; Sandra Zurawski; Jean-Philippe Blanck; Yanying Cao; Sandra Clayton; Jean-Pierre Gorvel; Gerard Zurawski; Eynav Klechevsky
Journal:  Blood       Date:  2012-04-25       Impact factor: 22.113

Review 3.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

4.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

5.  PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Authors:  Victor D Fedorov; Maria Themeli; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-12-11       Impact factor: 17.956

6.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

7.  Novel APC-like properties of human NK cells directly regulate T cell activation.

Authors:  Jacob Hanna; Tsufit Gonen-Gross; Jonathan Fitchett; Tony Rowe; Mark Daniels; Tal I Arnon; Roi Gazit; Aviva Joseph; Karoline W Schjetne; Alexander Steinle; Angel Porgador; Dror Mevorach; Debra Goldman-Wohl; Simcha Yagel; Michael J LaBarre; Jane H Buckner; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 8.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Peripheral blood CD40-CD40L expression in human breast cancer.

Authors:  W Pan; J Gong; C Yang; R Feng; F Guo; Y Sun; H Chen
Journal:  Ir J Med Sci       Date:  2013-02-28       Impact factor: 1.568

10.  Engineering higher affinity T cell receptors using a T cell display system.

Authors:  Adam S Chervin; David H Aggen; John M Raseman; David M Kranz
Journal:  J Immunol Methods       Date:  2008-10-12       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.